Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,970,756
  • Shares Outstanding, K 92,738
  • Annual Sales, $ 4,010 K
  • Annual Income, $ -214,530 K
  • EBIT $ -278 M
  • EBITDA $ -283 M
  • 60-Month Beta 0.60
  • Price/Sales 1,218.79
  • Price/Cash Flow N/A
  • Price/Book 5.07

Options Overview Details

View History
  • Implied Volatility 54.33% ( -0.64%)
  • Historical Volatility 47.99%
  • IV Percentile 34%
  • IV Rank 37.25%
  • IV High 88.58% on 03/15/24
  • IV Low 34.00% on 09/24/24
  • Put/Call Vol Ratio 0.29
  • Today's Volume 44
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 2,243
  • Open Int (30-Day) 2,342

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.92
  • Number of Estimates 8
  • High Estimate -0.80
  • Low Estimate -1.15
  • Prior Year -0.90
  • Growth Rate Est. (year over year) -2.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.81 +5.48%
on 12/19/24
60.34 -11.17%
on 12/11/24
-2.47 (-4.41%)
since 11/20/24
3-Month
49.13 +9.11%
on 09/24/24
62.53 -14.28%
on 11/14/24
+0.45 (+0.85%)
since 09/20/24
52-Week
33.67 +59.19%
on 01/05/24
62.53 -14.28%
on 11/14/24
+19.11 (+55.41%)
since 12/20/23

Most Recent Stories

More News
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

CRNX : 53.60 (+1.63%)
Crinetics Pharmaceuticals Grants Stock Options to New Employees Under 2021 Inducement Plan

Crinetics Pharmaceuticals granted stock options to 16 new employees under its 2021 Inducement Plan, totaling 146,400 shares.Quiver AI SummaryCrinetics Pharmaceuticals, Inc. announced the grant of non-qualified...

CRNX : 53.60 (+1.63%)
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 53.60 (+1.63%)
Crinetics Pharmaceuticals Announces FDA Acceptance of NDA for Paltusotine to Treat Acromegaly

Crinetics Pharmaceuticals' paltusotine NDA accepted by FDA, offering a potential new oral treatment for acromegaly.Quiver AI SummaryCrinetics Pharmaceuticals, Inc. announced that the FDA has accepted its...

CRNX : 53.60 (+1.63%)
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

CRNX : 53.60 (+1.63%)
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

CRNX : 53.60 (+1.63%)
Crinetics Pharmaceuticals to Showcase Novel Nonpeptide Drug Conjugate Platform and Phase 2 Data for Paltusotine at NANETS 2024

Crinetics Pharmaceuticals will present preclinical data on CRN09682 and Paltusotine at NANETS 2024.Quiver AI SummaryCrinetics Pharmaceuticals, Inc. announced the debut of its innovative nonpeptide drug...

CRNX : 53.60 (+1.63%)
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

CRNX : 53.60 (+1.63%)
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

CRNX : 53.60 (+1.63%)
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

CRNX : 53.60 (+1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly,...

See More

Key Turning Points

3rd Resistance Point 57.18
2nd Resistance Point 55.71
1st Resistance Point 54.66
Last Price 53.60
1st Support Level 52.14
2nd Support Level 50.67
3rd Support Level 49.62

See More

52-Week High 62.53
Last Price 53.60
Fibonacci 61.8% 51.51
Fibonacci 50% 48.10
Fibonacci 38.2% 44.69
52-Week Low 33.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar